RE: £17 target9 Apr 2021 18:42
'So the latter, along with his clinical pharmacist colleague, Aurélien Mary, decided to work with two infectious diseases specialists from the University Hospital of Amiens, Jean-Philippe Lanoix and Jean-Luc Schmit, to conduct research on these famous interferons. “In April, resuscitators agreed to use this method of inhalation on four patients affected by the coronavirus and who were at a therapeutic impasse. The patients got away with it, ”explains Michel Brazier.
One trial on 146 patients
What if the trail is really the right one? Experiments on an artificial lung are encouraging. A larger clinical trial becomes necessary to validate the hypothesis.
Trial which will not be able to begin until the fall, with the rebound of the epidemic. "There were no longer enough patients in hospitals from May," says the Amiens researcher. Aid from the Hauts-de-France regional council of 130,000 euros (two-thirds of the cost of the study) is granted in October.
The study can take shape. It concerns 146 patients throughout the region. After the hospitals of Abbeville, Saint-Quentin or Valenciennes, that of Compiègne, this week, then of Tourcoing and Montreuil-sur-Mer, the next few weeks, will participate. “We are working with Novartis laboratories which supplies the interferons. For about ten minutes, patients in the initial viral phase inhale these proteins synthesized using a mask on the nose and mouth, ”summarizes Michel Brazier.
A similar study in England
In parallel with the research directed at the Amiens hospital, a trial on outpatient patients is being carried out in Bordeaux. "We hope to have a reliable answer, during the month of June," he slips.
But the study would not be finished. A third phase would then be necessary to definitively validate the protocol. Unless a similar study on interferons, carried out by the English laboratory Synairgen and the University of Southampton, completes its work more quickly than the French, allowing the treatment to be brought to market more quickly.'
Sign In
Follow the stocks
